117

7-[2-(4-FLUORO-PHENYL)-5-ISOPROPYL-3-PHENYL-4-PHENYLCARBAMOYL-PYRROL-1-YL]- 3,5-DIHYDROXY-HEPTANOIC ACID

117 is found in 1 entries

117 as free ligands, exist in 1 entries. Examples include 1HWK,

Find related ligands: Stereoisomers Similar ligands Chemical Structure Search

View summary at Ligand Expo

Chemical Component Summary

Name 7-[2-(4-FLUORO-PHENYL)-5-ISOPROPYL-3-PHENYL-4-PHENYLCARBAMOYL-PYRROL-1-YL]- 3,5-DIHYDROXY-HEPTANOIC ACID
Identifiers (3R,5R)-7-[2-(4-fluorophenyl)-5-(1-methylethyl)-3-phenyl-4-(phenylcarbamoyl)-1H-pyrrol-1-yl]-3,5-dihydroxyheptanoic acid
(3R,5R)-7-[2-(4-fluorophenyl)-3-phenyl-4-(phenylcarbamoyl)-5-propan-2-yl-pyrrol-1-yl]-3,5-dihydroxy-heptanoic acid
Synonyms ATORVASTATIN
Formula C33 H35 F N2 O5
Molecular Weight 558.64 g/mol
Type non-polymer
Isomeric SMILES CC(C)c1c(C(=O)Nc2ccccc2)c(c(-c2ccc(F)cc2)n1CC[C@@H](O)C[C@@H](O)CC(O)=O)-c1ccccc1
InChI InChI=1S/C33H35FN2O5/c1-21(2)31-30(33(41)35-25-11-7-4-8-12-25)29(22-9-5-3-6-10-22)32(23-13-15-24(34)16-14-23)36(31)18-17-26(37)19-27(38)20-28(39)40/h3-16,21,26-27,37-38H,17-20H2,1-2H3,(H,35,41)(H,39,40)/t26-,27-/m1/s1
InChI Key XUKUURHRXDUEBC-KAYWLYCHSA-N

Chemical Details

Formal Charge 0
Atom Count 76
Chiral Atom Count 2
Chiral Atoms C3 C5
Bond Count 79
Aromatic Bond Count 25

Drug Info: DrugBank

DrugBank ID DB01076   (Different stereochemistry)
Name Atorvastatin
Groups approved
Description Atorvastatin (Lipitor) is a member of the drug class known as statins. It is used for lowering cholesterol. Atorvastatin is a competitive inhibitor of hydroxymethylglutaryl-coenzyme A (HMG-CoA) reductase, the rate-determining enzyme in cholesterol biosynthesis via the mevalonate pathway. HMG-CoA reductase catalyzes the conversion of HMG-CoA to mevalonate. Atorvastatin acts primarily in the liver. Decreased hepatic cholesterol levels increases hepatic uptake of cholesterol and reduces plasma cholesterol levels.
Synonyms Lipovastatinklonal
Salts
  • Atorvastatin Calcium
  • Atorvastatin calcium trihydrate
Brand Names
  • Act Atorvastatin
  • Amlodipine Besylate and Atorvastatin Calcium
  • Amlodipine Besylate/atorvastatin Calcium
  • Apo-amlodipine-atorvastatin
  • Apo-atorvastatin
  • Atorvastatin
  • Atorvastatin Calcium
  • Atorvastatin-10
  • Atorvastatin-20
  • Atorvastatin-40
  • Atorvastatin-80
  • Auro-atorvastatin
  • Ava-atorvastatin
  • Caduet
  • Dom-atorvastatin
  • Gd-amlodipine/atorvastatin
  • Gd-atorvastatin
  • Jamp-atorvastatin
  • Lipitor
  • Liptruzet
  • Mylan-amlodipine/atorvastatin
  • Mylan-atorvastatin
  • Novo-atorvastatin
  • Ntp-atorvastatin
  • PMS-amlodipine-atorvastatin
  • PMS-atorvastatin
  • Pendo-amlodipine-atorvastatin
  • Q-gen Atorvastatin
  • Ran-atorvastatin
  • Ratio-atorvastatin
  • Rbx-atorvastatin
  • Reddy-atorvastatin
  • Riva-atorvastatin
  • Sandoz Atorvastatin
  • Atogal
  • Cardyl
  • Faboxim
  • Hipolixan
  • Lipotropic
  • Liprimar
  • Lowden
  • Normalip
  • Sincol
  • Sortis
  • Torvacard
  • Torvast
  • Totalip
  • Tulip
  • Vastina
  • Xanator
  • Xarator
  • Zurinel
[more]
Affected Organism Humans and other mammals
Indication May be used as primary prevention in individuals with multiple risk factors for coronary heart disease (CHD) and as secondary prevention in individuals with CHD to reduce the risk of myocardial infarction (MI), stroke, angina, and revascularization procedures. May be used to reduce the risk of cardiovascular events in patients with acute coronary syndrome (ACS). May be used in the treatment of primary hypercholesterolemia and mixed dyslipidemia, homozygous familial hypercholesterolemia, primary dysbetalipoproteinemia, and/or hypertriglyeridemia as an adjunct to dietary therapy to decrease serum total and low-density lipoprotein cholesterol (LDL-C), apolipoprotein B (apoB), and triglyceride concentrations, while increasing high-density lipoprotein cholesterol (HDL-C) levels.
Pharmacology Atorvastatin, a selective, competitive HMG-CoA reductase inhibitor, is used to lower serum total and LDL cholesterol, apoB, and triglyceride levels while increasing HDL cholesterol. High LDL-C, low HDL-C and high TG concentrations in the plasma are associated with increased risk of atherosclerosis and cardiovascular disease. The total cholesterol to HDL-C ratio is a strong predictor of coronary artery disease and high ratios are associated with higher risk of disease. Increased levels of HDL-C are associated with lower cardiovascular risk. By decreasing LDL-C and TG and increasing HDL-C, atorvastatin reduces the risk of cardiovascular morbidity and mortality. Atorvastatin has a unique structure, long half-life, and hepatic selectivity, explaining its greater LDL-lowering potency compared to other HMG-CoA reductase inhibitors.
Mechanism of action Atorvastatin selectively and competitively inhibits the hepatic enzyme HMG-CoA reductase. As HMG-CoA reductase is responsible for converting HMG-CoA to mevalonate in the cholesterol biosynthesis pathway, this results in a subsequent decrease in hepatic cholesterol levels. Decreased hepatic cholesterol levels stimulates upregulation of hepatic LDL-C receptors which increases hepatic uptake of LDL-C and reduces serum LDL-C concentrations.
Route of administration oral
Categories
  • Anticholesteremic Agents
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors
ATC-Code C10AA05
AHFS-Code 24:06.08
CAS number 134523-00-5
Drug Info/Drug Targets: DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS. Nucleic Acids Res. 2011 Jan; 39 (Database issue):D1035-41. | PMID: 21059682